Dr. Marvin S. Hausman, the Chairman of Nova’s Scientific Advisory Board, delivered a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome at the 18th NFXF International Fragile X Conference in July 2022.

Nova’s recent research results showed that a very low microdose formulation of our proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects in a genetic model of FXS.